Joe Jimenez

facebook_page
twitter_page

Last quote by Joe Jimenez

We look at everything, the bigger the target the higher the premium seems to be right now. We have gone upstream, and, if you heard, in the fourth quarter we announced four transactions that were quite early-stage, but they supplement the pipelines of our innovative medicines divisions.
Jan 25 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Joe Jimenez is associated, including Novartis, U.S., and pricing. Most recently, Joe Jimenez has been quoted saying: “We are going to look at what's in the best interest of our shareholders, in terms of the future of that business, ranging all the way from retaining the business to a capital markets exit through an IPO or a spin. We're going to take 2017 to do that and we will be back with an update on that by the end of this year. Novartis recognized this a couple of years ago and we started down a path of contracting based on the outcomes that the drug delivered instead of just the transaction of getting a particular price.” in the article We’re looking at all options for our struggling eye care business: Novartis CEO.
Automatically powered byStoryzy

Joe Jimenez quotes

Building the framework needed to support value-based pricing, and the infrastructure of data and systems required to achieve them, is a priority for us.

We expect pricing to become more difficult in the U.S. over the next three to five years.

Novartis delivered a solid Q3 despite the Gleevec generic impact in the US, due to the strong performance of our growth products.

No quotes...
More Joe Jimenez quotes

Quotes by Joe Jimenez

<
>
facebook_page
twitter_page